Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | MME | P08473 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.45 |
| ▸ | CPA1 | P15085 | 1/20 | 0.45 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CRHBP | P24387 | 1/20 | 0.42 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27250348 | 1.00 | FOLH1 (0.49) | FOLH1TAAR1SLC6A2MMEACE | |
| SCHEMBL13254075 | 0.87 | CYP1A2 (0.39) | FOLH1MMEACECPA1ACE2 | |
| SCHEMBL16171970 | 0.87 | ACACB (0.43) | SMN1; SMN2MMP9 | |
| SCHEMBL23306913 | 0.87 | ACACB (0.43) | SMN1; SMN2MMP9 | |
| SCHEMBL23660888 | 0.87 | ACACB (0.43) | SMN1; SMN2MMP9 | |
| SCHEMBL23584052 | 0.86 | ACE (0.48) | FOLH1TAAR1SLC6A2MMEACE | |
| SCHEMBL23306926 | 0.85 | NPC1 (0.42) | MME | |
| SCHEMBL680890 | 0.85 | ACACB (0.44) | SLC6A2GAASMN1; SMN2TSHR | |
| SCHEMBL20892764 | 0.85 | ACACB (0.44) | SLC6A2GAASMN1; SMN2TSHR | |
| SCHEMBL23660917 | 0.85 | TRPA1 (0.45) | MMEACECPA1ACE2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240072809-A1 | ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | AVILAR THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | UNIV YALE (US) | 2023-07-27 | — | — | US | disclosed |
| US-20220177514-A1 | A METHOD FOR FUNCTIONALIZATION OF AN AROMATIC AMINO ACID OR A NUCLEOBASE | CF Plus Chemicals s.r.o. (CZ) | 2022-06-09 | — | — | US | disclosed |
| US-11046695-B2 | Fragment synthesis of substituted cyclic peptides | ZEALAND PHARMA A/S (DK) | 2021-06-29 | — | — | US | disclosed |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | LI MING HSIN (TW) | 2021-04-29 | — | — | US | disclosed |
| US-10981921-B2 | Fragment synthesis of substituted cyclic peptides | ZEALAND PHARMA A/S (DK) | 2021-04-20 | — | — | US | disclosed |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | NORTHWEST UNIVERSITY (CN) | 2017-09-21 | — | — | US | disclosed |
| US-9393187-B2 | Peptide compounds that inhibit neuronal exocytosis | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | LUBRIZOL ADVANCED MATERIALS, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8946166-B2 | Peptide-based compounds and compositions which inhibit muscle contraction | LIPOTEC, S.A. (ES) | 2015-02-03 | — | — | US | disclosed |
| US-8653278-B2 | Isoform selective HDAC inhibitors | GEORGETOWN UNIVERSITY (US) | 2014-02-18 | — | — | US | disclosed |
| US-8357654-B2 | Multimeric CD40 ligands, method for preparing same and use thereof for preparing drugs | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | LIPOTEC, S.A. (ES) | 2012-05-17 | — | — | US | disclosed |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | GEORGETOWN UNIVERSITY (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-07-22 | — | — | US | disclosed |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11819551-B2 | ASGPR-binding compounds for the degradation of extracellular proteins | ASGR1, ENGASE, FCGR2A | FOLH1 661/4885TAAR1 1450/4885SLC6A2 3181/4885 |
| US-20100183642-A1 | NOVEL MULTIMERIC CD40 LIGANDS, METHOD FOR PREPARING SAME AND USE THEREOF FOR PREPARING DRUGS | CD40, CD40LG, TNFSF10 | FOLH1 1077/4885TAAR1 1772/4885SLC6A2 3038/4885 |
| US-20220177514-A1 | A METHOD FOR FUNCTIONALIZATION OF AN AROMATIC AMINO ACID OR A NUCLEOBASE | DDC, SLC38A7, PFAS | FOLH1 207/4885TAAR1 336/4885SLC6A2 311/4885 |
| US-20100136034-A1 | NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS | TNFRSF1A, TNFRSF9, CD40 | FOLH1 1788/4885TAAR1 490/4885SLC6A2 4869/4885 |
| US-20230233689-A1 | Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins | ASGR1, LDLR, FCGR2A | FOLH1 961/4885TAAR1 1481/4885SLC6A2 4167/4885 |
| US-11046695-B2 | Fragment synthesis of substituted cyclic peptides | VIP, NPPA, NGLY1 | FOLH1 89/4885TAAR1 4136/4885SLC6A2 4814/4885 |
| US-20120121675-A1 | COMPOUNDS WHICH INHIBIT MUSCLE CONTRACTION | ATP2A3, MYLK2, MYL6 | FOLH1 4450/4885TAAR1 686/4885SLC6A2 1733/4885 |
| US-10981921-B2 | Fragment synthesis of substituted cyclic peptides | VIP, NPPA, NGLY1 | FOLH1 89/4885TAAR1 4136/4885SLC6A2 4814/4885 |
| US-20240239828-A1 | MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS | M6PR, ASGR1, IGF2R | FOLH1 542/4885TAAR1 1216/4885SLC6A2 2647/4885 |
| US-20100196502-A1 | Isoform Selective HDAC Inhibitors | HDAC5, HDAC6, HDAC3 | FOLH1 1292/4885TAAR1 4289/4885SLC6A2 4128/4885 |
| US-20210121585-A1 | PSMA targeted radiotherapy medicine and preparation method thereof | FOLH1, KLK3, PSMA1 | FOLH1 1/4885TAAR1 471/4885SLC6A2 2950/4885 |
| US-20150071974-A1 | COMPOUNDS WHICH INHIBIT NEURONAL EXOCYTOSIS | SLC18A2, SLC18A1, ATP6V1B2 | FOLH1 3668/4885TAAR1 212/4885SLC6A2 51/4885 |
| US-20170267718-A1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | VIP, PREP, ACE | FOLH1 114/4885TAAR1 2612/4885SLC6A2 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.